Daromun injections for advanced melanoma
This trial tests Daromun, an injected treatment for advanced melanoma that has not responded to immunotherapy or cannot use it. It looks at how safe and effective Daromun is when given directly into skin tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage IIIB, IIIC, or IIID melanoma that has spread to nearby lymph nodes or skin.
- Your melanoma started in the skin or from an unknown place, not in the eye or mouth.
- Your disease got worse after a type of treatment called immunotherapy, or you cannot have immunotherapy.
- You have already received at least one injection of Daromun into a tumor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an injected medicine placed directly into melanoma tumors before surgery can improve outcomes for melanoma that has spread to nearby lymph nodes/skin but can still be fully removed. It aims to shrink the cancer and reduce the chance it comes back after surgery.
This study tests two different ways of giving immunotherapy drugs (anti-CTLA-4 and anti-PD-1 checkpoint inhibitors) to treat advanced melanoma that cannot be surgically removed. Researchers want to see if giving one drug through the skin (intradermal) instead of through the vein works as well or better.
This trial tests a new combination of drugs (iparomlimab, tuvoraleimab, bevacizumab, and chemotherapy) as a first or second treatment for advanced acral or mucosal melanoma. It aims to see if this mix can help shrink or control the cancer.
This study tests a new approach for advanced melanoma that is not responding to standard immunotherapy (like pembrolizumab). It combines a targeted injection directly into the tumor (L19IL2, L19TNF, or both) with pembrolizumab. The goal is to see if this combination can shrink tumors and help the immune system fight the cancer.
This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
Hear when a new Injections Intralesional trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.